Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center

Articles by Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center

Evaluating Tumor Biology in HR+ Metastatic Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

January 29th 2021

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026

Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC